Paul Mischel, M.D.
Affiliations: | Pathology | University of California, San Diego, La Jolla, CA |
Area:
EGFR/PI3K/Akt/mTOR signaling networkWebsite:
http://www.ludwigcancerresearch.org/location/san-diego-branch/paul-s-mischel-labGoogle:
"Paul Mischel"Children
Sign in to add traineeFeng Feng Liu | post-doc | UCSD | |
Beatrice Gini | post-doc | UCSD | |
Kenta Masui | post-doc | UCSD | |
Tomoo Matsutani | post-doc | UCSD |
Collaborators
Sign in to add collaboratorNational Brain Tumor Society | collaborator | National Brain Tumor Society |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Dehkordi SR, Wong IT, Ni J, et al. (2023) Breakage fusion bridge cycles drive high oncogene copy number, but not intratumoral genetic heterogeneity or rapid cancer genome change. Biorxiv : the Preprint Server For Biology |
Masui K, Mischel PS. (2023) Metabolic and epigenetic reprogramming in the pathogenesis of glioblastoma: Toward the establishment of "metabolism-based pathology". Pathology International. 73: 533-541 |
Raviram R, Raman A, Preissl S, et al. (2023) Integrated analysis of single-cell chromatin state and transcriptome identified common vulnerability despite glioblastoma heterogeneity. Proceedings of the National Academy of Sciences of the United States of America. 120: e2210991120 |
West TJ, Bi J, Martínez-Peña F, et al. (2023) A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death. Journal of the American Chemical Society |
Pecorino LT, Verhaak RGW, Henssen A, et al. (2022) Extrachromosomal DNA (ecDNA): an origin of tumor heterogeneity, genomic remodeling, and drug resistance. Biochemical Society Transactions |
Chen PB, Fiaux PC, Zhang K, et al. (2022) Systematic discovery and functional dissection of enhancers needed for cancer cell fitness and proliferation. Cell Reports. 41: 111630 |
Noorani I, Mischel PS, Swanton C. (2022) Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges. Nature Reviews. Clinical Oncology |
Lange JT, Rose JC, Chen CY, et al. (2022) The evolutionary dynamics of extrachromosomal DNA in human cancers. Nature Genetics |
Masui K, Cavenee WK, Mischel PS, et al. (2022) The metabolomic landscape plays a critical role in glioma oncogenesis. Cancer Science |
Bi J, Khan A, Tang J, et al. (2021) Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports. 37: 109957 |